Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2012 3
2013 1
2014 3
2015 4
2016 2
2017 3
2018 1
2019 4
2020 4
2021 10
2022 17
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates.
Du Y, Liang Z, Wang S, Sun D, Wang X, Liew SY, Lu S, Wu S, Jiang Y, Wang Y, Zhang B, Yu W, Lu Z, Pu Y, Zhang Y, Long H, Xiao S, Liang R, Zhang Z, Guan J, Wang J, Ren H, Wei Y, Zhao J, Sun S, Liu T, Meng G, Wang L, Gu J, Wang T, Liu Y, Li C, Tang C, Shen Z, Peng X, Deng H. Du Y, et al. Among authors: xiao s. Nat Med. 2022 Feb;28(2):272-282. doi: 10.1038/s41591-021-01645-7. Epub 2022 Feb 3. Nat Med. 2022. PMID: 35115708
Diagnosing and grading gastric atrophy and intestinal metaplasia using semi-supervised deep learning on pathological images: development and validation study.
Fang S, Liu Z, Qiu Q, Tang Z, Yang Y, Kuang Z, Du X, Xiao S, Liu Y, Luo Y, Gu L, Tian L, Liang X, Fan G, Zhang Y, Zhang P, Zhou W, Liu X, Tian J, Wei W. Fang S, et al. Among authors: xiao s. Gastric Cancer. 2024 Mar;27(2):343-354. doi: 10.1007/s10120-023-01451-9. Epub 2023 Dec 14. Gastric Cancer. 2024. PMID: 38095766 Free PMC article. Clinical Trial.
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J, Wang T, Yang Y, Huang J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wang H, Cang S, Wu N, Song W, Liu X, Zhao S, Ding L, Selvaggi G, Wang Y, Xiao S, Wang Q, Shen Z, Zhou J, Zhou J, Zhang L. Zheng J, et al. Among authors: xiao s. Cancer Commun (Lond). 2024 Apr;44(4):455-468. doi: 10.1002/cac2.12524. Epub 2024 Feb 29. Cancer Commun (Lond). 2024. PMID: 38421881 Free PMC article. Clinical Trial.
58 results